About Pluristem Therapeutics Inc.:
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe inflammatory and ischemic disorders.
The Pluristem Therapeutics Inc. logo is available at
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we discuss our public offering and its anticipated closing date. Any such statements, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, and other risk factors discussed in the company's Annual Report on Form 10-K for the year ended June 30, 2012 and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. Except as otherwise required by law, the company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Daya Lettvin
Investor & Media Relations Director
MATAM Park, Building 20, Haifa 31905, Israel